Kévin Bouiller

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader, Maude Bouscambert‐Duchamp, Maya Hites et al. · The Lancet Infectious Diseases · 2021 · 338 citations · Full text

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Jérôme Avouac, Élodie Drumez, É. Hachulla et al. · The Lancet Rheumatology · 2021 · 290 citations · Full text

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +9

Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort

Nadège Néant, Guillaume Lingas, Quentin Le Hingrat et al. · Proceedings of the National Academy of Sciences · 2021 · 248 citations · Full text

Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients

Basile Mouhat, Matthieu Besutti, Kévin Bouiller et al. · European Respiratory Journal · 2020 · 134 citations · Full text

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

Florence Ader, Nathan Peiffer‐Smadja, Julien Poissy et al. · Clinical Microbiology and Infection · 2021 · 102 citations · Full text

Clinical Infectious Disease, Open-label Randomized, Antiviral Drug Development +6